Faron Pharmaceuticals Oy (OHEL:FARON) FFO

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OHEL:FARON Faron Pharmaceuticals Oy OHEL:FARON
18 GF Score
Price €0.48
! 4 Warning Signs
View Full Analysis

What is Faron Pharmaceuticals Oy FFO?

FFO (Funds from operations) only applies to REITs.

OHEL:FARON
18GF Score
Faron Pharmaceuticals Oy OHEL:FARON
FFO is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Faron Pharmaceuticals Oy Business Description

Other Exchanges FARN:UK4FR:Germany
Address Joukahaisenkatu 6 B, Turku, FIN, 20520
Faron Pharmaceuticals Oy is a clinical-stage biopharmaceutical company. The company has one operating and reportable segment. The Group has a pipeline based on the receptors involved in the regulation of immune response in oncology, organ damage, and bone marrow regeneration. Faron is a late clinical stage drug discovery and development Group. The company includes Bexmarilimab in its pipeline. Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and improve clinical outcomes by targeting myeloid cell function in the microenvironment and igniting the immune system against cancer.
18GF Score

Get the complete analysis for OHEL:FARON

FFO is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€0.48
Price